Amanda Armstrong, MD, MPH, introduces the evolving CSU landscape and outlines key objectives: guideline alignment, treatment optimization, and integration of new targeted agents.

Discussion on differentiating spontaneous from inducible urticaria, identifying triggers, and streamlining diagnosis in dermatology and primary care.

Review of updated CSU treatment algorithms and the balance between standardized and individualized care approaches.

Exploration of using tools such as UAS7 and DLQI to quantify disease severity, predict poor response, and guide timely therapy escalation.

Examination of REMIX-1 and REMIX-2 trial results demonstrating remibrutinib’s efficacy, durability, and potential for remission.

Strategies for counseling patients about biologic vs oral therapy, improving adherence, and addressing hesitancy or misconceptions.

Discussion on factors such as comorbidities, adherence, and access that influence the choice between oral BTK inhibitors and injectable biologics.

Amanda Armstrong, MD, MPH, predicts a move toward mechanism-based therapy selection and highlights biomarkers that could guide personalized treatment.

Closing insights on expanding dermatology’s leadership in CSU management and embracing innovation to enhance patient outcomes.